CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A, Pujade-Lauraine, E
Format:	Artigo
Sprog:	Inglês
Udgivet:	Nature Publishing Group 2012
Fag:	Clinical Studies
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3322951/ https://ncbi.nlm.nih.gov/pubmed/22240800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.593
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

Lignende værker